Tags : Simbrinza

Pharma

Alcon to Acquire Exclusive US Commercialization Rights to Novartis’ Simbrinza

Shots: Novartis to receive $355M following the closure of acquisition, which is expected to occur in Q2’21. The acquisition expands existing Alcon’s ophthalmic portfolio and strengthens its footprints in the US The companies will initiate a transition period where Novartis will continue to sell Simbrinza and transfer the profit to Alcon. Following the transition period, […]Read More